2 terminated, 2 unknown, 1 recruiting. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 2, Unknown 2, Recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow CKD: new trials by email Literature Review of CKD trials Research Report on CKD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis Veverimer, Placebo - CKD, Metabolic Acidosis | Phase 3 | Recruiting | Renibus Therapeutics, Inc. | 150 | 2026-01-13 | 2026-10-23 |
| ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE Placebo, Ravulizumab - Chronic Kidney Disease, CKD | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 555 | 2023-04-06 | 2026-10-29 |
| Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study Dapagliflozin - AKI - Acute Kidney Injury, Biomarkers | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 100 | 2023-01-01 | 2024-03-05 |
| The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients Sitagliptin - Covid19, Diabetes Mellitus, Type 2 | Phase 3 | Unknown | University of Milan | 170 | 2021-12-29 | 2021-09-28 |
| Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution - CKD, Diabetic Kidney Disease | Phase 3 | Terminated | Geisinger Clinic | 15 | 2021-07-23 | 2024-02-09 |
Renal Insufficiency, Chronic (2) · Acidosis (1) · Acute Kidney Injury (1) · COVID-19 (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Nephropathies (1) · Heart Diseases (1) · Obesity (1) · Obesity, Morbid (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Nutritional and Metabolic Diseases (3) · Renal Insufficiency (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Chronic Disease (2) · Diabetes Mellitus (2) · Disease Attributes (2) · Endocrine System Diseases (2) · Metabolic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Sitagliptin Phosphate (1) · dapagliflozin (1) · ravulizumab (1) · semaglutide (1) · veverimer (1)
Alexion Pharmaceuticals, Inc. (1) · Geisinger Clinic (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Renibus Therapeutics, Inc. (1) · University of Milan (1)
United States (3) · Italy (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · France (1) · Germany (1) · Hong Kong (1) · India (1) · Israel (1) · Japan (1) · Mexico (1) · Netherlands (1)
Alex R Chang, MD, MS (1) · Paolo Fiorina, MD, PhD (1) · Tolga Baykal, MD, PhD (1)